<DOC>
	<DOCNO>NCT00702572</DOCNO>
	<brief_summary>The primary objective study establish phase II recommend dose Vorinostat administer combination regimen carboplatin , paclitaxel bevacizumab patient previously untreated advanced non-small cell lunc cancer .</brief_summary>
	<brief_title>Carboplatin , Paclitaxel , Bevacizumab Vorinostat Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Since regimen bevacizumab , carboplatin paclitaxel become standard regimen treatment advance non-squamous NSCLC , new study patient population include reference arm . Addition fourth anti-cancer agent become new strategy improve outcome advanced non-squamous NSCLC . Since regimen Vorinostat , Carboplatin Paclitaxel already advance stage development important study safety tolerability Vorinostat combination three-drug regimen Bevacizumab , Carboplatin Paclitaxel . Therefore , evaluate Vorinostat administered combination regimen Carboplatin , Paclitaxel Bevacizumab patient previously untreated advanced non-small cell lung cancer .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Advanced nonsquamous NSCLC No prior chemotherapy advanced disease ECOG performance status 0 1 Measurable disease Life expectancy &gt; 3 month Normal bone marrow , renal hepatic function Ability take oral medication Willingness sign inform consent History brain metastasis Evidence thromboembolic phenomenon treatment anticoagulant Pregnancy Uncontrolled intercurrent illness Prior therapy Paclitaxel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Advanced non-small cell lung cancer</keyword>
</DOC>